Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The objective of this research study is to determine the safety and feasibility of chelation
therapy with deferoxamine for patients with iron overload who are receiving a stem cell
transplant. Patients who have iron overload prior to stem cell transplantation may have more
toxicity from the transplantation procedure, and thus may benefit from an attempt at iron
chelation pre- and peri-transplantation. In this study we are examining the use of
deferoxamine starting 2 weeks to 3 months prior to transplantation and continuing through the
preparative regimen.